Mitsubishi UFJ Asset Management Co. Ltd. Has $43.06 Million Stock Holdings in Biogen Inc. $BIIB

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in Biogen Inc. (NASDAQ:BIIB) by 4.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 307,379 shares of the biotechnology company’s stock after buying an additional 13,110 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.21% of Biogen worth $43,058,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BIIB. CVA Family Office LLC grew its position in Biogen by 18.1% in the 3rd quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock valued at $65,000 after purchasing an additional 71 shares during the period. TD Private Client Wealth LLC lifted its stake in shares of Biogen by 22.5% in the third quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after buying an additional 76 shares in the last quarter. CX Institutional grew its holdings in shares of Biogen by 6.1% during the third quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 83 shares during the last quarter. Rothschild Investment LLC raised its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares during the last quarter. Finally, True Wealth Design LLC lifted its position in Biogen by 62.9% in the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on BIIB shares. Mizuho increased their price objective on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Sanford C. Bernstein reissued a “market perform” rating on shares of Biogen in a research report on Monday, February 9th. Truist Financial lifted their price objective on shares of Biogen from $190.00 to $193.00 and gave the stock a “hold” rating in a report on Monday, February 9th. Morgan Stanley set a $190.00 target price on shares of Biogen in a report on Sunday, February 8th. Finally, Guggenheim boosted their price target on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $205.04.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $191.82 on Friday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The stock has a fifty day simple moving average of $181.98 and a two-hundred day simple moving average of $163.51. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41. The firm has a market cap of $28.15 billion, a price-to-earnings ratio of 21.77, a price-to-earnings-growth ratio of 1.52 and a beta of 0.16.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter in the prior year, the firm earned $3.44 EPS. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.18% of the stock is currently owned by company insiders.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.